Free Trial
NASDAQ:XBIO

Xenetic Biosciences Q2 2024 Earnings Report

Xenetic Biosciences logo
$2.38 -0.03 (-1.08%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$2.44 +0.06 (+2.31%)
As of 04/17/2025 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xenetic Biosciences EPS Results

Actual EPS
-$0.83
Consensus EPS
-$0.83
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Xenetic Biosciences Revenue Results

Actual Revenue
$0.73 million
Expected Revenue
$0.54 million
Beat/Miss
Beat by +$190.00 thousand
YoY Revenue Growth
N/A

Xenetic Biosciences Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Wednesday, August 14, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Xenetic Biosciences' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Friday, May 9, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Xenetic Biosciences Earnings Headlines

Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Drops By 22.2%
Will Trump match FDR's unprecedented FOUR terms?
Not since Franklin Delano Roosevelt has a U.S. President served more than two terms. The conventional wisdom says it would require a Constitutional amendment for this to happen again. But former Presidential advisor Jim Rickards, who has spent 50 years in Washington advising the CIA, Treasury, and four U.S. Presidents, believes the impossible is becoming probable. "The groundwork is being laid for a THIRD Trump Presidency," says Rickards.
Xenetic Biosciences (XBIO) Receives a Hold from H.C. Wainwright
See More Xenetic Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email.

About Xenetic Biosciences

Xenetic Biosciences (NASDAQ:XBIO), Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

View Xenetic Biosciences Profile

More Earnings Resources from MarketBeat